3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 3
3
Phase 2
2
Phase 1/2
2
Phase 4
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
2
Biochemically Recurrent Prostate Cancer
1
Interventions
pembrolizumab
66
Carboplatin
65
Paclitaxel
54
Magnetic Resonance Spectroscopy
45
Cisplatin
45
Specimen Handling
43
Gemcitabine
36
Docetaxel
31
Bevacizumab
31
Leucovorin
29
Doxorubicin
29
Dexamethasone
28
Fluorouracil
27
Pemetrexed
26
Cyclophosphamide
26
Oxaliplatin
24
Radiation
23
durvalumab
22
Radiotherapy
22
Letrozole
22
Etoposide
22
Nivolumab
21
Irinotecan
21
Vincristine
20
Rituximab
20
Capecitabine
20
Taxes
19
Prednisone
19
Lenalidomide
19
130-nm albumin-bound paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
darolutamide
×
30 days
×
Clear all
NCT07611110
2026-05-28
VECTRA-01
AstraZeneca
Phase 3
Recruiting
670 enrolled
NCT06120491
2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3
Active not recruiting
1,889 enrolled
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled